JAK‐inhibitors for dermatomyositis: A concise literature review

Aliza Paudyal,Ming Zheng,Ling Lyu,Christina Thapa,Shirui Gong,Yao Yang,Xiaoyan Lyu

DOI: https://doi.org/10.1111/dth.14939

2021-03-23

Dermatologic Therapy

Abstract:Refractory dermatomyositis is defined as cases that do not show improvement after initial treatment with two different immunosuppressives combined with corticosteroids with or without IVIGs. In recent years, few studies have reported a positive response to the use of Janus kinase inhibitors (JAK‐inhibitors) for the treatment of refractory dermatomyositis. A systematic literature review was performed for articles studying the use of JAK‐inhibitors for the treatment of refractory dermatomyositis. We identified 38 females and 15 males treated with JAK‐inhibitors without serious side effects. Tofacitinib was the most frequently used JAK‐inhibitor followed by Ruxolitinib. Significant improvement in CDASI score, muscle strength, body weight, and skin lesions were reported in most of the studies. The duration of follow‐up ranged from 1 to 15 months without relapse. Therefore, the use of JAK‐inhibitors looks promising in the treatment of refractory DM and further high volume research may be required to validate the current concept. As only case reports and series were identified without direct comparison for review, there is a potential risk of bias. Despite these limitations, we believe that the result of this analysis allows a better understanding of treatment options for refractory dermatomyositis and will help generate a hypothesis that can be further tested.This article is protected by copyright. All rights reserved.

dermatology